FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2559255020> ?p ?o ?g. }

• W2559255020 endingPage "411" @default.
• W2559255020 startingPage "402" @default.
• W2559255020 abstract "Purpose Retrospective studies indicate that expression of excision repair cross complementing group 1 (ERCC1) protein is associated with platinum resistance and survival in non–small-cell lung cancer (NSCLC). We conducted the first randomized trial, to our knowledge, to evaluate ERCC1 prospectively and to assess the superiority of nonplatinum therapy over platinum doublet therapy for ERCC1-positive NSCLC as well as noninferiority for ERCC1-negative NSCLC. Patients and Methods This trial had a marker-by-treatment interaction phase III design, with ERCC1 (8F1 antibody) status as a randomization stratification factor. Chemonaïve patients with NSCLC (stage IIIB and IV) were eligible. Patients with squamous histology were randomly assigned to cisplatin and gemcitabine or paclitaxel and gemcitabine; nonsquamous patients received cisplatin and pemetrexed or paclitaxel and pemetrexed. Primary end point was overall survival (OS). We also evaluated an antibody specific for XPF (clone 3F2). The target hazard ratio (HR) for patients with ERCC1-positive NSCLC was ≤ 0.78. Results Of patients, 648 were recruited (177 squamous, 471 nonsquamous). ERCC1-positive rates were 54.5% and 76.7% in nonsquamous and squamous patients, respectively, and the corresponding XPF-positive rates were 70.5% and 68.5%. Accrual stopped early in 2012 for squamous patients because OS for nonplatinum therapy was inferior to platinum therapy (median OS, 7.6 months [paclitaxel and gemcitabine] v 10.7 months [cisplatin and gemcitabine]; HR, 1.46; P = .02). Accrual for nonsquamous patients halted in 2013. Median OS was 8.0 (paclitaxel and pemetrexed) versus 9.6 (cisplatin and pemetrexed) months for ERCC1-positive patients (HR, 1.11; 95% CI, 0.85 to 1.44), and 10.3 (paclitaxel and pemetrexed) versus 11.6 (cisplatin and pemetrexed) months for ERCC1-negative patients (HR, 0.99; 95% CI, 0.73 to 1.33; interaction P = .64). OS HR was 1.09 (95% CI, 0.83 to 1.44) for XPF-positive patients, and 1.39 (95% CI, 0.90 to 2.15) for XPF-negative patients (interaction P = .35). Neither ERCC1 nor XPF were prognostic: among nonsquamous patients, OS HRs for positive versus negative were ERCC1, 1.11 ( P = .32), and XPF, 1.08 ( P = .55). Conclusion Superior outcomes were observed for patients with squamous histology who received platinum therapy compared with nonplatinum chemotherapy; however, selecting chemotherapy by using commercially available ERCC1 or XPF antibodies did not confer any extra survival benefit." @default.
• W2559255020 created "2016-12-08" @default.
• W2559255020 creator A5002621278 @default.
• W2559255020 creator A5003419213 @default.
• W2559255020 creator A5005554940 @default.
• W2559255020 creator A5010405819 @default.
• W2559255020 creator A5016828265 @default.
• W2559255020 creator A5019646420 @default.
• W2559255020 creator A5023781617 @default.
• W2559255020 creator A5024423770 @default.
• W2559255020 creator A5034748028 @default.
• W2559255020 creator A5035278067 @default.
• W2559255020 creator A5037200778 @default.
• W2559255020 creator A5037541807 @default.
• W2559255020 creator A5038725960 @default.
• W2559255020 creator A5045870974 @default.
• W2559255020 creator A5050113969 @default.
• W2559255020 creator A5051291310 @default.
• W2559255020 creator A5055057910 @default.
• W2559255020 creator A5060804162 @default.
• W2559255020 creator A5062675479 @default.
• W2559255020 creator A5068874700 @default.
• W2559255020 creator A5080195917 @default.
• W2559255020 creator A5089453687 @default.
• W2559255020 creator A5089954905 @default.
• W2559255020 date "2017-02-01" @default.
• W2559255020 modified "2023-10-01" @default.
• W2559255020 title "Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non–Small-Cell Lung Cancer: ERCC1 Trial (ET)" @default.
• W2559255020 cites W1555396697 @default.
• W2559255020 cites W1591524401 @default.
• W2559255020 cites W1966267239 @default.
• W2559255020 cites W1967827870 @default.
• W2559255020 cites W1980444814 @default.
• W2559255020 cites W1996251617 @default.
• W2559255020 cites W2004718750 @default.
• W2559255020 cites W2010624323 @default.
• W2559255020 cites W2017194759 @default.
• W2559255020 cites W2038544276 @default.
• W2559255020 cites W2049601212 @default.
• W2559255020 cites W2050648887 @default.
• W2559255020 cites W2058950201 @default.
• W2559255020 cites W2059186992 @default.
• W2559255020 cites W2062615242 @default.
• W2559255020 cites W2063563776 @default.
• W2559255020 cites W2065181085 @default.
• W2559255020 cites W2076597529 @default.
• W2559255020 cites W2080883315 @default.
• W2559255020 cites W2088847092 @default.
• W2559255020 cites W2099725888 @default.
• W2559255020 cites W2104468815 @default.
• W2559255020 cites W2119165414 @default.
• W2559255020 cites W2124537819 @default.
• W2559255020 cites W2135836212 @default.
• W2559255020 cites W2154267626 @default.
• W2559255020 cites W2155858243 @default.
• W2559255020 cites W2157216866 @default.
• W2559255020 cites W2163885210 @default.
• W2559255020 cites W2167571044 @default.
• W2559255020 cites W2173113817 @default.
• W2559255020 cites W2180444265 @default.
• W2559255020 cites W2259179874 @default.
• W2559255020 cites W2290020609 @default.
• W2559255020 cites W2397079377 @default.
• W2559255020 cites W2590506413 @default.
• W2559255020 doi "https://doi.org/10.1200/jco.2016.68.1841" @default.
• W2559255020 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27893326" @default.
• W2559255020 hasPublicationYear "2017" @default.
• W2559255020 type Work @default.
• W2559255020 sameAs 2559255020 @default.
• W2559255020 citedByCount "44" @default.
• W2559255020 countsByYear W25592550202016 @default.
• W2559255020 countsByYear W25592550202017 @default.
• W2559255020 countsByYear W25592550202018 @default.
• W2559255020 countsByYear W25592550202019 @default.
• W2559255020 countsByYear W25592550202020 @default.
• W2559255020 countsByYear W25592550202021 @default.
• W2559255020 countsByYear W25592550202022 @default.
• W2559255020 countsByYear W25592550202023 @default.
• W2559255020 crossrefType "journal-article" @default.
• W2559255020 hasAuthorship W2559255020A5002621278 @default.
• W2559255020 hasAuthorship W2559255020A5003419213 @default.
• W2559255020 hasAuthorship W2559255020A5005554940 @default.
• W2559255020 hasAuthorship W2559255020A5010405819 @default.
• W2559255020 hasAuthorship W2559255020A5016828265 @default.
• W2559255020 hasAuthorship W2559255020A5019646420 @default.
• W2559255020 hasAuthorship W2559255020A5023781617 @default.
• W2559255020 hasAuthorship W2559255020A5024423770 @default.
• W2559255020 hasAuthorship W2559255020A5034748028 @default.
• W2559255020 hasAuthorship W2559255020A5035278067 @default.
• W2559255020 hasAuthorship W2559255020A5037200778 @default.
• W2559255020 hasAuthorship W2559255020A5037541807 @default.
• W2559255020 hasAuthorship W2559255020A5038725960 @default.
• W2559255020 hasAuthorship W2559255020A5045870974 @default.
• W2559255020 hasAuthorship W2559255020A5050113969 @default.
• W2559255020 hasAuthorship W2559255020A5051291310 @default.
• W2559255020 hasAuthorship W2559255020A5055057910 @default.
• W2559255020 hasAuthorship W2559255020A5060804162 @default.
• W2559255020 hasAuthorship W2559255020A5062675479 @default.

• next